KR20160096194A - 상처 치료 방법 - Google Patents

상처 치료 방법 Download PDF

Info

Publication number
KR20160096194A
KR20160096194A KR1020167019187A KR20167019187A KR20160096194A KR 20160096194 A KR20160096194 A KR 20160096194A KR 1020167019187 A KR1020167019187 A KR 1020167019187A KR 20167019187 A KR20167019187 A KR 20167019187A KR 20160096194 A KR20160096194 A KR 20160096194A
Authority
KR
South Korea
Prior art keywords
wound
antibody
vegf
seq
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167019187A
Other languages
English (en)
Korean (ko)
Inventor
울프 에릭슨
아넬리 팔케발
아니카 멜렘
Original Assignee
씨에스엘 리미티드
비-크리에이티브 스웨덴 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904942A external-priority patent/AU2013904942A0/en
Application filed by 씨에스엘 리미티드, 비-크리에이티브 스웨덴 아베 filed Critical 씨에스엘 리미티드
Priority to KR1020227026917A priority Critical patent/KR102466794B1/ko
Publication of KR20160096194A publication Critical patent/KR20160096194A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167019187A 2013-12-18 2014-12-18 상처 치료 방법 Ceased KR20160096194A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227026917A KR102466794B1 (ko) 2013-12-18 2014-12-18 상처 치료 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2013904942A AU2013904942A0 (en) 2013-12-18 Method of treating wounds
AU2013904942 2013-12-18
AU2013904966 2013-12-19
AU2013904966A AU2013904966A0 (en) 2013-12-19 Method of treating wounds
PCT/AU2014/050431 WO2015089585A1 (en) 2013-12-18 2014-12-18 Method of treating wounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227026917A Division KR102466794B1 (ko) 2013-12-18 2014-12-18 상처 치료 방법

Publications (1)

Publication Number Publication Date
KR20160096194A true KR20160096194A (ko) 2016-08-12

Family

ID=53401804

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167019187A Ceased KR20160096194A (ko) 2013-12-18 2014-12-18 상처 치료 방법
KR1020227026917A Active KR102466794B1 (ko) 2013-12-18 2014-12-18 상처 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227026917A Active KR102466794B1 (ko) 2013-12-18 2014-12-18 상처 치료 방법

Country Status (13)

Country Link
US (1) US10543270B2 (enExample)
EP (1) EP3082860B1 (enExample)
JP (1) JP6553618B2 (enExample)
KR (2) KR20160096194A (enExample)
CN (1) CN105979965B (enExample)
AU (1) AU2014366837B2 (enExample)
BR (1) BR112016014099A2 (enExample)
CA (1) CA2932465C (enExample)
DK (1) DK3082860T3 (enExample)
ES (1) ES2851386T3 (enExample)
PL (1) PL3082860T3 (enExample)
RU (1) RU2672377C1 (enExample)
WO (1) WO2015089585A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3220952B1 (en) 2014-11-17 2021-04-21 CSL Limited Method of treating or preventing stroke
EP3445450A4 (en) * 2016-04-21 2020-01-08 CSL Limited METHOD FOR TREATING OR PREVENTING LIVER DISEASES
US20250042984A1 (en) * 2021-12-20 2025-02-06 CSL Innovation Pty Ltd Protein formulations and uses thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994007921A1 (en) 1992-09-25 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2374290T3 (es) 1998-03-20 2012-02-15 Commonwealth Scientific And Industrial Research Organisation Genes sintéticos y constructos genéticos que comprenden los mismos.
EP1068311B2 (en) 1998-04-08 2020-12-09 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
PT1390535E (pt) 2001-04-26 2010-10-04 Amgen Mountain View Inc Bibliotecas combinatórias de domínios monoméricos
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
EP1482975B1 (en) * 2002-01-29 2006-12-13 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Prevention of tissue adhesion
CA2429483A1 (en) 2002-05-17 2003-11-17 Amrad Operations Pty Ltd. Immunointeractive molecules
US20030232439A1 (en) 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US20070292416A1 (en) 2003-06-02 2007-12-20 Alexion Pharmaceuticals, Inc. De-Immunized Anti-Cd3 Antibody
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
KR20060129246A (ko) 2003-12-05 2006-12-15 컴파운드 쎄라퓨틱스, 인크. 타입 2 혈관 내피 성장 인자 수용체의 억제제
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
CA2567655C (en) 2004-06-02 2015-06-30 Diatech Pty Ltd Binding moieties based on shark ignar domains
AU2005269265B2 (en) 2004-08-02 2012-01-12 Zenyth Operations Pty Ltd A method of treating cancer comprising a VEGF-B antagonist
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007019620A1 (en) 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
US8871247B2 (en) * 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
US20100216865A1 (en) * 2007-09-12 2010-08-26 Elias Jack A MicroRNA COMPOSITIONS IN THE TREATMENT OF VEGF-MEDIATED DISORDERS
AU2009233718A1 (en) * 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
RU2395521C1 (ru) * 2008-11-10 2010-07-27 Учреждение Российской Академии Наук Институт Биологии Гена Ран Наноантитело v9, связывающее vegf, и способ его получения, кодирующая v9 нуклеотидная последовательность и содержащий ее вектор, способ ингибирования пролиферации эндотелиальных клеток
CN102369021B (zh) 2008-12-19 2016-09-07 宏观基因有限公司 共价双抗体及其用途
US9259507B2 (en) * 2009-04-21 2016-02-16 Warsaw Orthopedic, Inc. Tissue augmentation with active agent for wound healing
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires

Also Published As

Publication number Publication date
DK3082860T3 (da) 2021-01-25
RU2016127196A (ru) 2018-01-23
CN105979965A (zh) 2016-09-28
US10543270B2 (en) 2020-01-28
AU2014366837A1 (en) 2016-06-16
AU2014366837B2 (en) 2020-06-25
KR20220115815A (ko) 2022-08-18
WO2015089585A1 (en) 2015-06-25
CN105979965B (zh) 2021-07-09
EP3082860A4 (en) 2017-08-16
EP3082860B1 (en) 2020-11-25
EP3082860A1 (en) 2016-10-26
BR112016014099A2 (pt) 2017-10-10
JP6553618B2 (ja) 2019-07-31
CA2932465C (en) 2023-08-22
PL3082860T3 (pl) 2021-06-14
US20160319008A1 (en) 2016-11-03
ES2851386T3 (es) 2021-09-06
RU2672377C1 (ru) 2018-11-14
KR102466794B1 (ko) 2022-11-11
CA2932465A1 (en) 2015-06-25
JP2017501182A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
KR102366682B1 (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
KR102513989B1 (ko) 간 질환을 치료하거나 예방하는 방법
US10961304B2 (en) Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
JP6802342B2 (ja) 腎症を処置する方法
KR102466794B1 (ko) 상처 치료 방법
WO2024249444A2 (en) Wnt surrogate agents and methods for lacrimal gland regeneration
HK1228748B (en) Method of treating wounds
AU2023229284A1 (en) Methods and compositions for treating and preventing fibrosis
HK1242603B (en) Method of treating or preventing stroke

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160715

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191218

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210517

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220119

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210517

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220119

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210916

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20191218

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220502

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220420

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220119

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210916

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210517

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191218

X601 Decision of rejection after re-examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220803